FDA Rejects Capricor's Duchenne Cell Therapy Over Trial Data Flaws
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
The Food and Drug Administration sent a formal rejection letter on Nov. 20 declining to approve deramiocel, Capricor Therapeutics' cell therapy…
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
5 confirmed facts, 1 open question and 2 sources behind this story.